Hetts S W, Tsai T, Cooke D L, Amans M R, Settecase F, Moftakhar P, Dowd C F, Higashida R T, Lawton M T, Halbach V V
From the Departments of Radiology and Biomedical Imaging (S.W.H., T.T., D.L.C., M.R.A., F.S., P.M., C.F.D., R.T.H., V.V.H.)
From the Departments of Radiology and Biomedical Imaging (S.W.H., T.T., D.L.C., M.R.A., F.S., P.M., C.F.D., R.T.H., V.V.H.).
AJNR Am J Neuroradiol. 2015 Oct;36(10):1912-9. doi: 10.3174/ajnr.A4391. Epub 2015 Jul 23.
A minority of intracranial dural arteriovenous fistulas progress with time. We sought to determine features that predict progression and define outcomes of patients with progressive dural arteriovenous fistulas.
We performed a retrospective imaging and clinical record review of patients with intracranial dural arteriovenous fistula evaluated at our hospital.
Of 579 patients with intracranial dural arteriovenous fistulas, 545 had 1 fistula (mean age, 45 ± 23 years) and 34 (5.9%) had enlarging, de novo, multiple, or recurrent fistulas (mean age, 53 ± 20 years; P = .11). Among these 34 patients, 19 had progressive dural arteriovenous fistulas with de novo fistulas or fistula enlargement with time (mean age, 36 ± 25 years; progressive group) and 15 had multiple or recurrent but nonprogressive fistulas (mean age, 57 ± 13 years; P = .0059, nonprogressive group). Whereas all 6 children had fistula progression, only 13/28 adults (P = .020) progressed. Angioarchitectural correlates to chronically elevated intracranial venous pressures, including venous sinus dilation (41% versus 7%, P = .045) and pseudophlebitic cortical venous pattern (P = .048), were more common in patients with progressive disease than in those without progression. Patients with progressive disease received more treatments than those without progression (median, 5 versus 3; P = .0068), but as a group, they did not demonstrate worse clinical outcomes (median mRS, 1 and 1; P = .39). However, 3 young patients died from intracranial venous hypertension and intracranial hemorrhage related to progression of their fistulas despite extensive endovascular, surgical, and radiosurgical treatments.
Few patients with dural arteriovenous fistulas follow an aggressive, progressive clinical course despite treatment. Younger age at initial presentation and angioarchitectural correlates to venous hypertension may help identify these patients prospectively.
少数颅内硬脑膜动静脉瘘会随时间进展。我们试图确定预测进展的特征,并明确进展性硬脑膜动静脉瘘患者的预后。
我们对在我院接受评估的颅内硬脑膜动静脉瘘患者进行了回顾性影像学和临床记录审查。
在579例颅内硬脑膜动静脉瘘患者中,545例有1个瘘(平均年龄45±23岁),34例(5.9%)有扩大、新发、多发或复发性瘘(平均年龄53±20岁;P = 0.11)。在这34例患者中,19例有进展性硬脑膜动静脉瘘,伴有新发瘘或瘘随时间扩大(平均年龄36±25岁;进展组),15例有多发或复发性但非进展性瘘(平均年龄57±13岁;P = 0.0059,非进展组)。所有6例儿童均有瘘进展,而28例成人中只有13例(P = 0.020)进展。与慢性颅内静脉压升高相关的血管构筑学特征,包括静脉窦扩张(41%对7%,P = 0.045)和假静脉炎样皮质静脉模式(P = 0.048),在进展性疾病患者中比无进展患者更常见。进展性疾病患者接受的治疗比无进展患者更多(中位数分别为5次和3次;P = 0.0068),但作为一个群体,他们并未表现出更差的临床预后(中位数mRS分别为1和1;P = 0.39)。然而,3例年轻患者尽管接受了广泛的血管内、手术和放射外科治疗,仍死于与瘘进展相关的颅内静脉高压和颅内出血。
尽管进行了治疗,但很少有硬脑膜动静脉瘘患者遵循侵袭性、进展性的临床病程。初次就诊时年龄较小以及与静脉高压相关的血管构筑学特征可能有助于前瞻性地识别这些患者。